Generic Tegretol (Zeptol Tablets) – Product Information
Generic Tegretol (Zeptol Tablets) is used for treating certain types of epileptic seizures and treats severe pain of the jaw or cheek caused by a facial nerve problem (trigeminal neuralgia).
The active ingredient present in Generic Tegretol is Carbamazepine.
Carbamazepine is available as Biston, Calepsin, Carbatrol, Epitol, Equetro, Finlepsin, Sirtal, Stazepine, Telesmin, Tegretol, EPITAB XR, Teril, Timonil, Trimonil, Epimaz, Carbama/Carbamaze, Amizepin, Carzine, Mazetol, Tegrital, Tegrita, Zeptol, Karbapin, Hermolepsin, Degranol, and Tegretal.
Dosage And Administration
The recommended adult Oral dosage of Generic Tegretol (Zeptol Tablets) for adults is given below:
Adults and children over 12 years of age:
Initial: 200 mg twice a day.Increase at weekly intervals by adding up to 200 mg/day using a twice a day regimen until the optimal response is obtained. Dosage generally should not exceed 1000 mg daily in children 12-15 years of age, and 1200 mg daily in patients above 15 years of age.
Maintenance: Adjust dosage to the minimum effective level, usually 800-1200 mg daily.
Initial: On the first day, 100 mg twice a day for a total daily dose of 200 mg. This daily dose may be increased by up to 200 mg/day using increments of 100 mg every 12 hours, only as needed to achieve freedom from pain. Do not exceed 1200 mg daily.
Maintenance: Control of pain can be maintained in most patients with 400-800 mg daily. However, some patients may be maintained on as little as 200 mg daily, while others may require as much as 1200 mg daily.
Side Effects of Generic Tegretol (Zeptol Tablets)
The side effects reported in patients treated with Generic Tegretol are dizziness, drowsiness, unsteadiness, headache, ataxia, fatigue, diplopia, leukopenia, oedema, fluid retention, weight increase, hyponatraemia and blood osmolarity decreased, nausea, vomiting , and allergic skin reactions (dermatitis allergic, urticaria)
For more details on Generic Tegretol (Zeptol Tablets) please see the presentation below.